Generic competition, a complete response letter, a new acquisition and external pressures have created a perfect storm for UCB, leading the company to reduce its profit forecast for 2022.
After previously projecting a profit margin of 26% to 27% and earnings per share of €4.80 to €5.30 this year, UCB has revised those ranges to 21% to 22% and €3.70 to €4, respectively.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,